Recombinant adeno-associated virus vectors for gene therapy
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors are based on a non-pathogenic human parvovirus (AAV) that is unique in its ability to persist in human cells without causing any pathologic effects. Studies of the potential barriers to rAAV-mediated transduction of relatively resistant cells has led to an understanding of the mechanisms of cell attachment and entry, cytoplasmic translocation, nuclear entry, conversion to active double-stranded DNA, activation of transcription and establishment of persistent molecular forms. Each of these areas is individually discussed, as are recent applications in vivo in preclinical models and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 2×
“The delay of expression related to conversion to dsDNA can now be bypassed [55,56].”
BackgroundQuantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547 · cited 8×
“The strategy involves using the fact that AAV packages plus and minus strands and the vector is presumed to fold through the internal ITR and continue double-stranded binding throughout the genome.”
BackgroundInfluentialGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 2×
“AAV1 consistently expressed higher levels of serum AAT and erythropoietin after muscle injection, thus validating the use of alternative serotype [43].”
BackgroundInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“The pinching in of clathrin pits may be initiated by the GTPase activity of dynamin to some degree [22,51].”
BackgroundDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 1×
“The 10 kb scenario invokes the split intron approach, which is dependent on head-to-tail joining [75,76].”
BackgroundEndosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 4×
“In addition, targeting may be useful in non-permissive or poorly permissive cells, such as apical lung epithelial cells [36], pancreatic beta cells and vascular endothelial cells.”
BackgroundInfluentialGirod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 4×
“GIROD A, WOBUS CE, ZADORI Z et al.: The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity.”
BackgroundInfluentialTrans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 1×
“Capsid peptides in the GH loop [38] function primarily for interaction with cellular receptors.”
Background
Cited by
Wu, J., Zhao, W., Zhong, L., Han, Z., Li, B., Ma, W., Weigel-Kelley, K. A., Warrington, K. H., & Srivastava, A. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.088 · Cited by 108
Ostedgaard, L. S., Rokhlina, T., Karp, P. H., Lashmit, P., Afione, S., Schmidt, M., Zabner, J., Stinski, M. F., Chiorini, J. A., & Welsh, M. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409845102 · Cited by 105
Reich, S. J., Auricchio, A., Hildinger, M., Glover, E., Maguire, A. M., Wilson, J. M., & Bennett, J. (2003) · Human Gene Therapy · doi:10.1089/10430340360464697 · Cited by 96
Lin, S.-W., Hensley, S. E., Tatsis, N., Lasaro, M. O., & Ertl, H. C. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33138 · Cited by 88
“To test whether persistence of the rAAV2/7gag vector, which would be expected to remain transcriptionally active as has been shown for other rAAV vectors (55, 56), affected the gag-specific CD8+ T cell response, mice were immunized with 1011 gc AAV2/7gag or 1010 vp AdHu5gag as a control.”
BackgroundThe Promise of Gene Therapy For The Treatment of α-1 Antitrypsin Deficiency
Cruz, P. E., Mueller, C., & Flotte, T. R. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.9.1191 · Cited by 10
Self-citation
Metadata
- Authors
- Conlon, T. J., & Flotte, T. R.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2004-07
- Volume
- 4
- Issue
- 7
- Pages
- 1093-1101
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2057842018
- Cited by
- 49
- References
- 25
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant adeno-associated virus vectors for gene therapy. https://app.cochat.ai/papers/10.1517/14712598.4.7.1093
- The paper
- Conlon, T. J., & Flotte, T. R. (2004). Recombinant adeno-associated virus vectors for gene therapy. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.4.7.1093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.